Inhibitors in Patients with Congenital Bleeding Disorders Other Than Hemophilia

Massimo Franchini, Giuseppe Marano, Carlo Mengoli, Vanessa Piccinini, Simonetta Pupella, Stefania Vaglio, Giancarlo Maria Liumbruno

Research output: Contribution to journalArticlepeer-review


The most worrying complication of replacement therapy for severe hemophilia A and B is currently the occurrence of inhibitory alloantibodies against infused factor VIII and factor IX, respectively. Inhibitors compromise the management of hemorrhage in affected patients, with a considerable increase in complications, disability, and costs. While these alloantibodies have been extensively studied in the past years in hemophilia A and B, those occurring in patients with other inherited bleeding disorders are less well characterized and still poorly understood, mostly due to the rarity of these hemorrhagic conditions. This narrative review will deal with inhibitors arising in patients with inherited bleeding disorders other than “classical” hemophilia, focusing in particular on those developing in patients with congenital deficiency of coagulation factor V, factor VII, factor XI, and factor XIII.

Original languageEnglish
JournalSeminars in Thrombosis and Hemostasis
Publication statusAccepted/In press - Nov 17 2017


  • alloantibodies
  • congenital
  • inherited bleeding disorders
  • inhibitors

ASJC Scopus subject areas

  • Hematology
  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Inhibitors in Patients with Congenital Bleeding Disorders Other Than Hemophilia'. Together they form a unique fingerprint.

Cite this